GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » Ending Cash Position

Abliva AB (OSTO:ABLI) Ending Cash Position : kr31.16 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Abliva AB Ending Cash Position?

Abliva AB's Ending Cash Position for the quarter that ended in Mar. 2024 was kr31.16 Mil.

Abliva AB's quarterly Ending Cash Position declined from Sep. 2023 (kr58.64 Mil) to Dec. 2023 (kr57.66 Mil) and declined from Dec. 2023 (kr57.66 Mil) to Mar. 2024 (kr31.16 Mil).

Abliva AB's annual Ending Cash Position increased from Dec. 2021 (kr22.34 Mil) to Dec. 2022 (kr66.39 Mil) but then declined from Dec. 2022 (kr66.39 Mil) to Dec. 2023 (kr57.66 Mil).

Abliva AB Ending Cash Position Historical Data

The historical data trend for Abliva AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Ending Cash Position Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.32 61.64 22.34 66.39 57.66

Abliva AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.52 63.77 58.64 57.66 31.16

Abliva AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Abliva AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=66.392+-8.728
=57.66

Abliva AB's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=57.664+-26.508
=31.16

Abliva AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Abliva AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB (OSTO:ABLI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » Ending Cash Position
Comparable Companies
OSTO:ATORX XSAT:HAMLET B OSTO:BIOWKS OSTO:MAGLE OSTO:ACOU OSTO:KAN OSTO:ACTI OSTO:CLBIO OSTO:STABL OSTO:GUARD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NEVPF:USA NTP:Germany
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Website
https://www.abliva.com
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines